Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients

A Randomised Pilot Study to Compare the Effect of Pioglitazone and Metformin on Cardiovascular Morbidity and Mortality in Patients With Type 2 Diabetes

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00399204

Enrollment

Registered

2006-11-14

Start date

2006-01-31

Completion date

2012-12-31

Last updated

2019-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

The study aims to see if there is any significant difference in the cardiovascular outcomes in type 2 diabetes patients who are treated with pioglitazone or Metformin

Interventions

DRUGPioglitazone vs Metformin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

25 Years to 60 Years

Healthy volunteers

Inclusion criteria

1. Newly diagnosed (less than six months since diagnosis and not controlled on dietary modifications) type 2 diabetic patients of both sexes aged 25-60 years. 2. Ready to give written informed consent

Exclusion criteria

1. Presence of ketonuria 2. Severe concurrent, infection or illness 3. History of hypersensitivity to any study drug 4. Impaired renal function 5. Pulmonary insufficiency with hypoxemia 6. Severe hepatic disease 7. Congestive heart failure 8. History of myocardial infarction or angina(stable/unstable) 9. History of alcohol or drug abuse 10. Pregnant or lactating women -

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026